Yahoo Web Search

  1. Web results

  2. Amylin Pharmaceuticals, LLC: Private Company Information ...

    Amylin Pharmaceuticals, LLC, a biopharmaceutical company, engages in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and other diseases.

  3. Amylin Pharmaceuticals - Wikipedia

    Amylin Pharmaceuticals was a biopharmaceutical company based in San Diego, CA, that was founded in 1987.The company was engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases.

  4. BYDUREON (by Amylin Pharmaceuticals, LLC)

    INDICATIONS AND USAGE. BYDUREON is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (1.1, 14).

  5. Amylin Pharmaceutical - West Chester, Ohio, USA ...

    Amylin Pharmaceuticals is a biopharmaceutical firm located in San Diego, California, with over 1,000 employees in the US. Amylin has developed and gained approval for two first-in-class medicines for the treatment of type I and type II diabetes, Symlin (pramlintide acetate) injection and Byetta (exenatide) injection.


    Amylin Pharmaceuticals, Inc. (as predecessor in interest to Amylin Pharmaceuticals, LLC, “Amylin” or the “Company”) is filing this Post-Effective Amendment to its Registration Statements ...

  7. MYALEPT - Amylin Pharmaceuticals, LLC

    Amylin Pharmaceuticals, LLC: MYALEPT is a leptin analog indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency...


    Amylin Pharmaceuticals, LLC is a Florida Foreign Limited-Liability Company filed on November 16, 2012. The company's filing status is listed as Active and its File Number is M12000006396.

  9. Amylin Pharmaceuticals, Inc. Company Information |

    Amylin Pharmaceuticals, Inc. Amylin Pharmaceuticals, Inc. is now part of AstraZeneca. (December 2013) See: AstraZeneca

  10. AstraZeneca to acquire Bristol-Myers Squibb - AstraZeneca

    AstraZeneca and Bristol-Myers Squibb anticipate that subject to local consultation and legislation, approximately 4,100 Bristol-Myers Squibb employees dedicated to the diabetes business, including those at Amylin, will eventually transition to AstraZeneca.

  11. Bristol-Myers Squibb is a global biopharma company dedicated to discovering, developing and delivering innovative medicines to patients with serious diseases.